GPCR Structure Therapeutics Inc.
Financings ·
Leerink Partners LLC and Cantor Fitzgerald & Co. are the sales agents. About $58.5 million of ADSs had already been sold, leaving $341,478,784 of capacity after the supplement.
We have not published a story on Structure Therapeutics yet. When there is news, it will appear here.
Structure Therapeutics is a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for a wide range of chronic diseases with unmet medical need. Its platform combines structure-based drug discovery with computational chemistry to find small molecules against G-protein coupled receptors (GPCRs). Its most advanced candidate, aleniglipron (GSBR-1290), is an oral selective GLP-1 receptor agonist in five ongoing clinical studies for obesity, overweight and related conditions. The company also has two oral small molecule amylin receptor agonists: ACCG-2671, in Phase 1 clinical development, and ACCG-3535, selected as its second amylin development candidate. Its obesity pipeline includes preclinical discovery stage small molecules targeting glucose-dependent insulinotropic polypeptide and glucagon receptors, which the company says could be developed as monotherapies or in fixed dose combinations with its GLP-1 or amylin candidates. The text names type 2 diabetes, heart failure, sleep apnea, chronic kidney disease, MASH and osteoarthritis among the conditions these combinations could address.
| Product or program | What it is | Stage |
|---|---|---|
| aleniglipron | Oral selective GLP-1 receptor agonist for obesity and related conditions | five ongoing clinical studies |
| ACCG-2671 | Oral small molecule amylin receptor agonist | Phase 1 |
| ACCG-3535 | Second oral amylin receptor agonist development candidate | development candidate |
| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | $225.3 million | $108.8 million |
| Net income (loss) | -$141.2 million | -$122.5 million |
| Cash from operations | -$222.2 million | -$116.6 million |
| Cash and equivalents | $799.6 million | $169.5 million |
| Short-term investments | $646.6 million | $714.0 million |
Our latest story on this, dated May 7, 2026: "Structure Therapeutics raises its at-the-market limit to $400,000,000". The story links the filing or release it is based on. Read the story.
Structure Therapeutics Inc. trades under the ticker GPCR on NASDAQ.
Structure Therapeutics Inc. is listed on NASDAQ.
The SEC Central Index Key (CIK) for Structure Therapeutics Inc. is 1888886. Its filings are on SEC EDGAR.
213,929,572 shares as of 2026-07-31, per the cover page of its 10-Q filed 2026-08-06.
Our directory records Structure Therapeutics Inc. under United States.
Our directory classifies Structure Therapeutics Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Structure Therapeutics Inc. is US86366E1064.
aibio.space lists Structure Therapeutics Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as E9.
Structure Therapeutics is a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for a wide range of chronic diseases with unmet medical need. Its platform combines structure-based drug discovery with computational chemistry to find small molecules against G-protein coupled receptors (GPCRs).
aleniglipron: Oral selective GLP-1 receptor agonist for obesity and related conditions Stage: five ongoing clinical studies.
ACCG-2671: Oral small molecule amylin receptor agonist Stage: Phase 1.
Structure Therapeutics Inc. reported a net loss of $141.2 million for the fiscal year ended Dec 31, 2025, and used $222.2 million of cash in operations, per its annual report to the SEC.
$225.3 million in the fiscal year ended Dec 31, 2025, per its annual report.
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio